Publication

Article

Oncology & Biotech News

March 2011
Volume5
Issue 3

Palliative care shows surprising benefit

Author(s):

New research has shown that adding prompt palliative supportive care to standard treatment may not only improve mood and quality of life in cancer patients, but it may even extend survival.

Palliative Care Shows Surprising Benefits

New research published August 19, 2010, in the New England Journal of Medicine has shown that adding prompt palliative supportive care to standard treatment may not only improve mood and quality of life in cancer patients, but it may even extend survival. The study, which examined 151 metastatic non-small cell lung cancer patients, showed that those assigned to additional palliative care had a median survival of 11.6 months, compared to 8.9 months for those who received standard treatment alone. Palliative care helps the patient cope with symptom management, psychological and social effects and also serves as a spiritual aid. This type of comprehensive care helps the patients and their families handle the trauma of the illness, as well as helping them understand treatment options and cope with effects of their disease.

Related Videos
Steven H. Lin, MD, PhD
Haley M. Hill, PA-C, discusses the role of multidisciplinary management in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the next steps for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on tissue and liquid biopsies for biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the benefits of in-house biomarker testing in NSCLC.
Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on treatment planning after biomarker testing in NSCLC.